CD276 and leukemia: To address the question of persistence, we further characterized the BiCisCAR T cells in vivo by measuring the proportion of CAR T cells in mouse spleens 21 days after CAR T cell infusion in our model of NALM6 leukemia cells expressing either GPC2 or CD276.